Még nem toboroz
Open-label Study of Plozasiran in Adolescents (age 12 to <18 years) with Familial Chylomicronemia Syndrome
2026-526244-12-00· 3. fázis· Arrowhead Pharmaceuticals Inc.· Forrás
Még nem toboroz
Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
2026-526113-28-00· 4. fázis· Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.· Forrás
Még nem toboroz
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
Increasing Flu Vaccination Through Evidence-Based Nudges
NCT07941427· Istituto Clinico Humanitas· Forrás
Még nem toboroz
A Phase 1/2/3 Study of ATSN-201 Gene Therapy in Subjects with RS1-Associated X linked Retinoschisis
NCT05878860· 3. fázis· Atsena Therapeutics Inc.· Forrás
Toboroz
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· 2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
International study on RD03/2016 eye drops compared to Leviosa® eye drops for the prevention and treatment of inflammation and the prevention of infections associated with cataract surgery in adults – FAST 7
2026-525594-39-00· 3. fázis· Ntc S.r.l.· Forrás
Még nem toboroz
A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00· 2. fázis· Kymera Therapeutics Inc.· Forrás
Toboroz
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546· 2. fázis· Biogen· Forrás
Toboroz
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951· 2. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Toboroz
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with
Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· 3. fázis· Janssen Cilag International· Forrás
Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Meghívásos bevonás
A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
NCT07632404· Novo Nordisk A/S· Forrás
Toboroz
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
2025-523180-38-00· 2. fázis· Kymera Therapeutics Inc.· Forrás
Toboroz
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
NCT07216235· 3. fázis· Zydus Therapeutics Inc.· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· 2/3. fázis· Pfizer· Forrás
Toboroz
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· 2. fázis· ViiV Healthcare· Forrás
Toboroz
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· 3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
2024-519836-18-00· 3. fázis· Newron Pharmaceuticals S.p.A.· Forrás
Toboroz
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
NCT07107529· 2. fázis· European Myeloma Network B.V.· Forrás
Toboroz
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269· 2. fázis· ADARx Pharmaceuticals, Inc.· Forrás
Toboroz
Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis
2023-503634-50-01· 3. fázis· Genexine Inc.· Forrás
Toboroz
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
NCT07284121· Hoffmann-La Roche· Forrás
Toboroz
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268· 2/3. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· 3. fázis· Sanofi· Forrás
Toboroz
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990· 2/3. fázis· Bicara Therapeutics· Forrás
Fut, nem toboroz
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179· 2. fázis· Laboratoires Thea· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· 3. fázis· ViiV Healthcare· Forrás
Toboroz
Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
NCT06635525· Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico· Forrás
Toboroz
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524· 2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373· 3. fázis· Priovant Therapeutics, Inc.· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Meghívásos bevonás
Long-term Safety and Tolerability of BHV-7000
NCT06443463· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)
2023-509551-14-00· 3. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· 3. fázis· Pfizer· Forrás
Toboroz
Rescue Stenting and Intravenous Thrombolysis In Patients With Large Vessel Ischemic Stroke
NCT06727006· ASST Santi Paolo e Carlo· Forrás
Toboroz
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· 3. fázis· Gilead Sciences· Forrás
Toboroz
Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
NCT05649943· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Forrás
Toboroz
Neurosurgical Outcome Network
NCT06724029· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Forrás
Toboroz
The Italian Transthyretin Amyloidosis Web-Network
NCT05444920· Fondazione IRCCS Policlinico San Matteo di Pavia· Forrás
Toboroz
Post COVID-19 Condition
NCT05531773· Euresist Network GEIE· Forrás
Fut, nem toboroz
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348· 3. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· 3. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Showing 50 of 57.